Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Chemical Regulation topic
No spam. Unsubscribe anytime.
SB 1306 would align California with federal exemptions for GBL mixtures used in semiconductor manufacturing
Summary
Sen. Cortese’s SB 1306 would exempt certain industrial mixtures containing gamma‑butyrolactone (GBL) from stricter state controls to reduce regulatory burden on semiconductor suppliers; industry witnesses urged consent placement and argued diversion risk is effectively zero.
Senator Cortese presented SB 1306 to align California law with federal DEA exemptions for certain industrial chemical mixtures containing gamma‑butyrolactone (GBL) at concentrations of 70% or less, saying the change would relieve regulatory burdens on suppliers for semiconductor manufacturing and research.
Cortese said federal DEA rules adopted in 2010 recognize that extracting pure GBL from complex industrial mixtures is not practically feasible, and that California’s current rules impose permitting, reporting, and transaction holds that raise costs and risk moving semiconductor activity out of state. Anthony Sampson, representing the semiconductor supply chain organization Semi, said the bill originally began as a consent item and that opposition letters reflected misunderstandings of the bill’s text.
Witnesses and the author emphasized the bill does not alter requirements for purchase, storage, or use of pure GBL and that the mixtures at issue typically contain small percentages of GBL; they urged the committee to pass the bill to Appropriations. No on‑the‑record opposition witnesses appeared at the hearing; the item was ordered to Appropriations and put "on call."
